Heron Therapeutics Inc HRTX's Sustol has endured a seemingly endless delay in its FDA approval process, and Slingshot Insights conducted an expert conference call on Thursday to discuss the matter. In addition to the potential for FDA approval, the expert discussed where Sustol could fit in the treatment of chemotherapy induced nausea and vomiting (CINV).
Slingshot's expert is a researcher of nervous system malignancies and is an assistant professor at the Preston Robert Tisch Brain Tumor Center.
Sustol has a new set of trial results that could help the drug overcome pervious FDA rejections. If approved, the drug could replace the current common treatment for CINV, which includes a combination of three different drugs.
Related Link: The July Stock Rally Will Continue
One potential issue that the drug could face is the already crowded market for treatment of CINV.
Shares of Heron Therapeutics are down 54.6 percent in the past year, as Sustol has thus far failed to gain approval. The company has reported that the FDA has not requested any further data from Heron related to Sustol, leaving many investors to question the long delay.
Slingshot’s conference call took place on Thursday morning, and the full transcript and audio recording can be found by clicking here.
Disclosure: the author holds no position in the stocks mentioned.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
